A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody can bind VEGF-A to inhibit its binding to VEGF receptor-2 (VEGFR-2), and then inhibit the biological effects of VEGF, including affecting vascular permeability, proliferation and endothelial cell migration and survival, so as to inhibit tumor angiogenesis, growth and metastasis. The gene discussed is KDR; the disease is neoplasm.